HUTCHMED (China) Limited reported interim results showing consolidated revenue of $278.29 million for the six months ended 30 June 2026, broadly flat year-on-year. Revenue from Oncology/Immunology rose 13% to $162.32 million, while revenue from Other Ventures fell 14% to $116.00 million as low-margin distribution volumes were scaled back.
Net income attributable to shareholders totalled $15.90 million versus $455.00 million a year earlier, when results were boosted by a $416.30 million one-off gain from the partial divestment of Shanghai Hutchison Pharmaceuticals. Excluding financing cash flows, the group recorded a net cash inflow of $10.50 million.
Oncology in-market sales increased 19% to $279.80 million, driven by China product growth of 32%. Key brands advanced: ELUNATE® sales in China climbed 41% to $60.80 million, SULANDA® rose 45% to $18.40 million and FRUZAQLA® ex-US jumped about 70% to $68.90 million. ORPATHYS® revenue increased 48% to $13.30 million as manufacturing volumes rose ahead of launch for third-line MET-amplified gastric cancer.
Cost of revenue declined to $152.16 million, reflecting efficiency gains; however, total operating expenses remained elevated at $277.42 million, with research and development spending up 9% to $78.78 million and selling and administrative costs up 12% to $46.48 million.
Cash, cash equivalents and short-term investments stood at $1.37 billion on 30 June 2026, up marginally from year-end 2025. Net gearing remained low at 7.4%; unutilised bank facilities reached $43.04 million.
Regulatory milestones included China approval of fruquintinib plus sintilimab for second-line renal cell carcinoma and approval of savolitinib for third-line MET-amplified gastric cancer. Sovleplenib secured priority-review NDA status in China for both immune thrombocytopenia and warm autoimmune hemolytic anemia, while fanregratinib’s NDA for cholangiocarcinoma is under priority review. Three first-in-class Antibody-Targeted Therapy Conjugates—HMPL-A251, HMPL-A580 and HMPL-A830—entered or prepared to enter early-stage global trials.
Management confirmed continued investment in R&D and active pursuit of multinational partnerships, supported by the company’s strengthened liquidity position and an MSCI ESG rating upgrade to “AA.”